Ravindranath Patel

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Richard S. Finn, John Crown, István Láng et al. · The Lancet Oncology · 2014 · 1.9K citations

Medicine, Oncology, Pharmacology +17

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 284 citations · Full text

Medicine, Oncology, Pharmacology +13

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

Richard S. Finn, John Crown, Johannes Ettl et al. · Breast Cancer Research · 2016 · 185 citations · Full text

Medicine, Oncology, Pharmacology +17

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

Richard S. Finn, Katalin Boér, Igor Bondarenko et al. · Breast Cancer Research and Treatment · 2020 · 170 citations · Full text

Medicine, Oncology, Pharmacology +17

A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

Zishuo Ian Hu, Johanna C. Bendell, Andrea J. Bullock et al. · Cancer Medicine · 2019 · 81 citations · Full text

Medicine, Oncology, Pharmacology +17